For the second quarter of FY2023, SHATTUCK LABS ($NASDAQ:STTK) reported total revenue of USD 0.2 million, representing a year-over-year increase from the USD 0.1 million recorded in the same period of the prior year. Net income for the quarter was reported as USD -21.4 million, which is a decrease compared to the -27.4 million reported in the corresponding period last year.
On Thursday, SHATTUCK LABS reported its second quarter FY2023 earnings results as of June 30 2023. The stock opened at $2.4 and closed at $2.2, representing a 8.6% decrease from its prior closing price of 2.4. The earnings report revealed that SHATTUCK LABS has seen a slight decrease in revenue compared to the same period last year.
While sales have slowed, the company has seen some progress in terms of customer growth and expansion in international markets. The results demonstrate that SHATTUCK LABS is feeling the effects of the current economic climate, yet remains resilient in the face of adversity. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Shattuck Labs. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Shattuck Labs. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Shattuck Labs. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Shattuck Labs are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Shattuck Labs Intrinsic Value Calculator
At GoodWhale, we conducted an analysis of SHATTUCK LABS‘s fundamentals and calculated the intrinsic value of its share to be around $7.0. This figure was obtained through our proprietary Valuation Line. Currently, SHATTUCK LABS stock is trading at $2.2, indicating a strong undervaluation of 68.7%. This could be an attractive opportunity for investors who are willing to invest for the long term and bear risks associated with market volatility. More…
Risk Rating Analysis
Star Chart Analysis
The company’s lead product candidate is SL-279252, a T-cell engaging antibody targeting CD47, which is in Phase 1/2 clinical trials for the treatment of solid tumors. Shattuck Labs is headquartered in South San Francisco, California. eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. The company’s lead product candidate is eFT508, a first-in-class, selective inhibitor of the MNK1/2 kinases. eFFECTOR is headquartered in San Diego, California. Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company focused on the development of novel cell-based therapies to treat cancer and other serious diseases. The company’s lead product candidates are CLBS03 and CLBS12, which are in Phase 2 clinical trials for the treatment of leukemia and multiple sclerosis, respectively. Caladrius is headquartered in New York, New York. Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. The company’s lead product candidate is VT-1161, an antagonist of the checkpoint receptor TIM3. Ventyx is headquartered in Menlo Park, California.
– eFFECTOR Therapeutics Inc ($NASDAQ:EFTR)
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of small molecule drugs to treat cancer and other diseases. The company’s market cap is 22.63M as of 2022 and its ROE is 30.82%. eFFECTOR Therapeutics Inc has a strong focus on the development of small molecule drugs to treat cancer and other diseases. The company’s clinical-stage products include EFT-101, which is in clinical development for the treatment of solid tumors, and EFT-102, which is in clinical development for the treatment of hematologic malignancies.
– Caladrius Biosciences Inc ($NASDAQ:CLBS)
Ventyx Biosciences Inc is a pharmaceutical company with a market cap of 1.5B as of 2022 and a Return on Equity of -18.15%. The company focuses on the development and commercialization of innovative therapies for the treatment of serious illnesses.
SHATTUCK LABS’ second quarter financial results for FY2023 show a total revenue increase of USD 0.1 million from the same period last year. Consequently, its stock price moved downwards on the same day. Investors should be aware that whilst revenue is up, the company is still running at a net loss, and watch the stock price closely. It is possible that future financial results could indicate further increases in revenue and decreases in net income, confirming a positive trend.